New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
04:55 EDTBAX, BAX, BAX, BAX, NVDQ, NVDQ, NVDQ, NVDQ, RTIX, RTIX, RTIX, RTIX, SYK, SYK, SYK, SYK, TFX, TFX, TFX, TFX, GIVN, GIVN, GIVN, GIVN, EW, EW, EW, EW, ETRM, ETRM, ETRM, ETRM, ECIA, ECIA, ECIA, ECIA, COV, COV, COV, COV, CNMD, CNMD, CNMD, CNMD, CFN, CFN, CFN, CFN, CADX, CADX, CADX, CADX, BSX, BSX, BSX, BSX, NPSP, NPSP, NPSP, NPSPSociety of American Gastrointestinal & Endoscopic Surgeons holds annual meeting
2014 Annual Meeting of SAGES is being held in Salt Lake City, Utah on April 2-5.
News For BAX;BSX;CADX;CFN;CNMD;COV;ECIA;ETRM;EW;GIVN;TFX;SYK;RTIX;NVDQ;NPSP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 23, 2015
08:57 EDTBAXBaxter still sees separation costs just above $300M, or 2% of sales
Subscribe for More Information
08:41 EDTBAXBaxter says separation of two companies on track for mid-2015
Subscribe for More Information
08:16 EDTRTIXRTI Surgical sees Q2 EPS 4c, consensus 4c
Subscribe for More Information
08:16 EDTRTIXRTI Surgical raises 2015 EPS outlook to 19c-23c from 17c-22c
Subscribe for More Information
08:14 EDTRTIXRTI Surgical reports Q1 EPS 5c, consensus 3c
Subscribe for More Information
07:21 EDTBAXBaxter sees Q2 continuing ops EPS 92c-96c, consensus $1.01
The company expects sales growth of approximately 1%, excluding the impact of foreign currency. Including the impact of foreign currency, the company expects sales to decline approximately 9%-10%. Consensus is $3.92B. Baxter also expects earnings from continuing operations, before special items, of 92c-96c per diluted share. The Q2 earnings guidance excludes approximately 8c per diluted share of projected intangible amortization expense. Reconciling for the inclusion of intangible asset amortization results in expected GAAP earnings of 84c-88c per diluted share, before other special items, for the quarter.
07:01 EDTBAXBaxter reports Q1 adjusted EPS $1.00, consensus 88c
Subscribe for More Information
April 22, 2015
16:19 EDTCNMDCONMED sees FY15 adjusted EPS $1.82-$1.92, consensus $1.86
The company reiterated its previously disclosed constant currency sales guidance, which calls for organic sales growth in 2015 to be in the range of 1%-3%. If foreign currency exchange rates hold near current levels, the company expects net sales for the last three quarters of 2015 to be negatively impacted by $3.9M as compared to prior sales guidance, which was based on January 23 currency rates. Using current exchange rates, CONMED now anticipates that reported sales for 2015 will be in the range of $723M-$738M, consensus $732.62M.
16:18 EDTCNMDCONMED reports Q1 adjusted EPS 42c, consensus 43c
Reports Q1 revenue $177.9M, consensus $174.98M.
15:50 EDTBAXNotable companies reporting before tomorrow's open
Subscribe for More Information
08:49 EDTBAXCTI BioPharma, Baxter to announce Phase 3 pacritinib data at ASCO late-breaker
CTI BioPharma (CTIC) and Baxter (BAX) announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology, or ASCO, meeting, to be held May 29-June 2 in Chicago. These data have also been selected as part of this year's official ASCO press briefing titled "Targeted Therapy" to be held on Saturday, May 30, at 8:00 am CT, the companies said.
07:11 EDTTFXCardiovascular & Interventional Radiological Society of Europe holds conference
Subscribe for More Information
April 21, 2015
16:43 EDTSYKStryker sees FY15 constant currency sales growth of 6%-7%, consensus $9.95B
Subscribe for More Information
16:41 EDTSYKStryker sees Q2 adjusted EPS $1.15-$1.20, consensus $1.17
If foreign currency exchange rates hold near current levels, we expect sales in the second quarter to be negatively impacted by approximately 3.5% to 4.5%, consensus $2.42B.
16:05 EDTSYKStryker revises FY15 adjusted EPS view to $4.95-$5.10 from $4.90-$5.10
Subscribe for More Information
16:03 EDTSYKStryker reports Q1 adjusted EPS $1.11, consensus $1.08
Subscribe for More Information
15:28 EDTSYKNotable companies reporting after market close
Subscribe for More Information
09:09 EDTBAXJPMorgan medical tech & devices analyst holds analyst/industry conference call
Subscribe for More Information
April 20, 2015
16:09 EDTBSXBoston Scientific announces long-term data underscore safety, efficacy of S-ICD
The Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific S-ICD System for patients at risk of sudden cardiac arrest. The study, "Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-year Results from a Pooled Analysis of the IDE Study and EFFORTLESS Registry" was led by Dr. Martin Burke, professor of medicine at the University of Chicago. The analysis combined data from two large S-ICD studies to provide the most comprehensive look at S-ICD System patient outcomes to date. The all-cause mortality rate for the S-ICD patients was 1.6% per year, comparing favorably to observed mortality rates in similar TV-ICD studies. Currently, the S-ICD System is covered nationally by Medicare, Aetna, Cigna and others, and regionally by numerous private and Medicaid plans, providing coverage for approximately 170M individuals in the U.S. The S-ICD System has been commercially available in Europe since 2009.
07:44 EDTBSXSurvey shows strong momentum for Boston Scientific devices, says RBC Capital
RBC Capital says that its survey supports strong momentum for Boston Scientific's S-ICD and Watchman, and the firm thinks the company is probably gaining share in single-chamber ICDs. The firm raised its price target on the shares to $20 from $17 and recommends buying the shares at current levels or on pullbacks.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use